SC-75416 |CAS#215122-74-0 |cyclooxygenase-2 inhibitor | postoperative inflammation

MedKoo Cat#: 53017 | Name: SC-75416

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SC-75416 is a cyclooxygenase-2 (COX-2) inhibitor potentially for the treatment of postoperative inflammation.

Chemical Structure

SC-75416

CAS#215122-74-0

Theoretical Analysis

MedKoo Cat#: 53017

Name: SC-75416

CAS#: 215122-74-0

Chemical Formula: C15H14ClF3O3

Exact Mass: 334.0600

Molecular Weight: 334.72

Elemental Analysis: C, 53.83; H, 4.22; Cl, 10.59; F, 17.03; O, 14.34

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

SC-75416; SC75416; SC 75416; tigemocoxibum; tigemocoxib

IUPAC/Chemical Name

(S)-7-(tert-butyl)-6-chloro-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid

InChi Key

InChi Code

SMILES Code

O=C(C1=CC2=CC(Cl)=C(C(C)(C)C)C=C2O[C@@H]1C(F)(F)F)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 334.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kowalski KG, Olson S, Remmers AE, Hutmacher MM. Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. Clin Pharmacol Ther. 2008 Jun;83(6):857-66. PubMed PMID: 17882158. 2: Salazar F, Salazar FJ, Saez F, Reverte V, Zweifel B, Dufield D, Radabaugh M, Graneto M, Llinas MT, Masferrer JL. Leukotrienes, but not angiotensin II, are involved in the renal effects elicited by the prolonged cyclooxygenase-2 inhibition when sodium intake is low. J Cardiovasc Pharmacol. 2013 Apr;61(4):329-36. doi: 10.1097/FJC.0b013e31828399ae. PubMed PMID: 23288201. 3: Wang JL, Limburg D, Graneto MJ, Springer J, Hamper JR, Liao S, Pawlitz JL, Kurumbail RG, Maziasz T, Talley JJ, Kiefer JR, Carter J. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7159-63. doi: 10.1016/j.bmcl.2010.07.054. PubMed PMID: 20709553. 4: Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur J Pharmacol. 2008 Jun 24;588(1):93-8. doi: 10.1016/j.ejphar.2008.03.057. PubMed PMID: 18457826. 5: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):467-509. PubMed PMID: 17982511.